Literature DB >> 18616965

Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon?

Katherine L B Borden1.   

Abstract

The promyelocytic leukemia protein PML and its associated nuclear bodies are hot topics of investigation. This interest arises for multiple reasons including the tight link between the integrity of PML nuclear bodies and several disease states and the impact of the PML protein and PML nuclear bodies on proliferation, apoptosis and viral infection. Unfortunately, an understanding of the molecular underpinnings of PML nuclear body function remains elusive. Here, a general overview of the PML field is provided and is extended to discuss whether some of the basic tenets of "PML-ology" are still valid. For instance, recent findings suggest that some components of PML nuclear bodies form bodies in the absence of the PML protein. Also, a new model for PML nuclear body function is proposed which provides a unifying framework for its effects on diverse biochemical pathways such as Akt signaling and the p53-Mdm2 axis. In this model, the PML protein acts as an inhibitor of gene expression post-transcriptionally via inhibiting a network node in the eIF4E RNA regulon. An example is given for how the PML RNA regulon model provided the basis for the development of a new anti-cancer strategy being tested in the clinic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18616965      PMCID: PMC2652867          DOI: 10.1016/j.bbamcr.2008.06.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  117 in total

1.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras.

Authors:  M Pearson; R Carbone; C Sebastiani; M Cioce; M Fagioli; S Saito; Y Higashimoto; E Appella; S Minucci; P P Pandolfi; P G Pelicci
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

2.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

3.  Role of SUMO-1-modified PML in nuclear body formation.

Authors:  S Zhong; S Müller; S Ronchetti; P S Freemont; A Dejean; P P Pandolfi
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

Review 4.  Review: properties and assembly mechanisms of ND10, PML bodies, or PODs.

Authors:  G G Maul; D Negorev; P Bell; A M Ishov
Journal:  J Struct Biol       Date:  2000-04       Impact factor: 2.867

5.  Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1.

Authors:  A Tan; P Bitterman; N Sonenberg; M Peterson; V Polunovsky
Journal:  Oncogene       Date:  2000-03-09       Impact factor: 9.867

6.  The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.

Authors:  H K Lai; K L Borden
Journal:  Oncogene       Date:  2000-03-23       Impact factor: 9.867

7.  Identification of a SUMO-binding motif that recognizes SUMO-modified proteins.

Authors:  Jing Song; Linda K Durrin; Thomas A Wilkinson; Theodore G Krontiris; Yuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-23       Impact factor: 11.205

8.  PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication.

Authors:  Asne Jul-Larsen; Therese Visted; Bård Ove Karlsen; Christine Hanssen Rinaldo; Rolf Bjerkvig; Per Eystein Lønning; Stig Ove Bøe
Journal:  Exp Cell Res       Date:  2004-08-01       Impact factor: 3.905

9.  The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3' splice site.

Authors:  X D Fu; T Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  Identification of a novel nuclear domain.

Authors:  C A Ascoli; G G Maul
Journal:  J Cell Biol       Date:  1991-03       Impact factor: 10.539

View more
  15 in total

1.  N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.

Authors:  Prashant Sharma; Rodolfo Murillas; Huafeng Zhang; Michael R Kuehn
Journal:  J Cell Sci       Date:  2010-03-16       Impact factor: 5.285

2.  Segmentation of fluorescence microscopy images for quantitative analysis of cell nuclear architecture.

Authors:  Richard A Russell; Niall M Adams; David A Stephens; Elizabeth Batty; Kirsten Jensen; Paul S Freemont
Journal:  Biophys J       Date:  2009-04-22       Impact factor: 4.033

3.  Mitogen-activated protein kinase-mediated licensing of interferon regulatory factor 3/7 reinforces the cell response to virus.

Authors:  Sonja Schmid; David Sachs; Benjamin R tenOever
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

Review 4.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

5.  The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation.

Authors:  Eva-Maria Schilling; Myriam Scherer; Nina Reuter; Johannes Schweininger; Yves A Muller; Thomas Stamminger
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 6.  Impact of nuclear organization and dynamics on epigenetic regulation in the central nervous system: implications for neurological disease states.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Ann N Y Acad Sci       Date:  2010-09       Impact factor: 5.691

Review 7.  The Arc of cognition: Signaling cascades regulating Arc and implications for cognitive function and disease.

Authors:  Irina Epstein; Steven Finkbeiner
Journal:  Semin Cell Dev Biol       Date:  2018-05       Impact factor: 7.727

8.  Regulation of the tumor suppressor PML by sequential post-translational modifications.

Authors:  M Lienhard Schmitz; Inna Grishina
Journal:  Front Oncol       Date:  2012-12-31       Impact factor: 6.244

9.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

Review 10.  The Arc of synaptic memory.

Authors:  Clive R Bramham; Maria N Alme; Margarethe Bittins; Sjoukje D Kuipers; Rajeevkumar R Nair; Balagopal Pai; Debabrata Panja; Manja Schubert; Jonathan Soule; Adrian Tiron; Karin Wibrand
Journal:  Exp Brain Res       Date:  2009-08-19       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.